In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

4SC grants resminostat rights to Yakult Honsha

Executive Summary

Japanese pharmaceutical and nutritional foods company Yakult Honsha Co. Ltd. is continuing to grow its cancer business, signing its second deal in the space this year. 4SC AG (autoimmune and oncology therapeutics) has granted Yakult exclusive rights to develop and sell its Phase II pan-histone-deacetylase (HDAC) inhibitor resminostat in Japan.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies